Preclinical News and Research

RSS
Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Viropharma announces financial results for second quarter of 2013

Viropharma announces financial results for second quarter of 2013

Miniscule signaling molecule plays critical role in certain acute and chronic diseases

Miniscule signaling molecule plays critical role in certain acute and chronic diseases

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Research finds potential long-term effects of marijuana use in adolescence

Research finds potential long-term effects of marijuana use in adolescence

Mda-9/syntenin helps regulate bladder cancer growth and metastasis

Mda-9/syntenin helps regulate bladder cancer growth and metastasis

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

New procedures to improve quality and usefulness of preclinical efficacy studies

New procedures to improve quality and usefulness of preclinical efficacy studies

Research team receives NCI grant to develop precision therapies that kill cancer cells

Research team receives NCI grant to develop precision therapies that kill cancer cells

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

HemoShear announces milestone in development of predictive drug safety systems

HemoShear announces milestone in development of predictive drug safety systems

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.